OS Therapies’ Post

CAK has been recognized as a promising target for cancer therapeutics and a potential target for antiviral treatments. The high-resolution cryo-EM structures offer profound insights for structure-based drug design. Cushing, V.I., Koh, A.F., Feng, J. et al. High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. Nat Commun 15, 2265 (2024). https://lnkd.in/gE9xAPkZ

The analysts from Leerink Partners have indicated that JANX007, a tumor-activated T cell engager known as TRACTr, has the potential to compete effectively with radioligand therapy such as Pluvicto and antibody-drug conjugates. They foresee that the risk-adjusted peak sales of JANX007 may reach $1.5 billion by 2035. JANX007 targets both prostate-specific membrane antigen (PSMA) and CD3, showing promising potential in the field of cancer treatment.

Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer. In this webinar, Dr. Sai Wang, protein senior scientist at GenScript Biotech Singapore, will discuss the advantages of bispecific antibodies (bsAbs), their mechanism of action (MOA), and the development history of bsAb platform. #bispecificantibodies #therapeutics #cancer #bsAbs #webinar

Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer. In this webinar, Dr. Sai Wang, protein senior scientist at GenScript Biotech Singapore, will discuss the advantages of bispecific antibodies (bsAbs), their mechanism of action (MOA), and the development history of bsAb platform. #bispecificantibodies #therapeutics #cancer #bsAbs #webinar

🔎 PROTEINA Case Study: Unveiling BCL2 PPI network 🔬 Discover our approach to investigating BCL2 PPI biomarkers to reveal the therapeutic impact of Venetoclax, the first FDA-approved BCL2 inhibitor, in transforming the treatment of hematologic malignancies. 📣 Takeaway: Assessing the efficacy of anti-cancer treatment has been always a primary objective for cancer drug developers. Our innovative SPID platform allows in-depth analysis of 47 distinct metrics including 20 different protein-protein interactions within the BCL2 family, providing a thorough quantitative assessment of apoptosis signaling from clinical samples of patients undergoing treatment. Check out the poster below to find out more about PROTEINA’s discovery, presented by our chief scientist, Byoungsan Choi at #AACR2024. Read a full abstract by clicking here: https://lnkd.in/gcJ7knrr   #PROTEINA #SPIDPlatform #CaseStudy #PPIBiomarker #BCL2Inhibitor #BCL2Family #MultipleMyeloma #Venetoclax  

Many types of cancer are initially susceptible to chemotherapy, over time they can develop resistance to traditional therapies through different mechanisms, such as drug inactivation, epigenetics, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and epithelial mesenchymal transition (EMT). These mechanisms promote direct or indirect drug resistance in human cancer cells, acting independently or in combination and through various signal transduction pathways.

At Cortalix we are developing CTX001, a single-domain antibody to target the PDGF beta Receptor (CD140b) in fibrosis and cancer. See why the PDGF beta Receptor is such an interesting novel radiopharmaceutical target.   #PETimaging #TRT #singledomainantibody #nanobody #PDGFR #CD140b

Did you know that there are nearly 61,000 new cancer cases per year in the US that harbor RASG12D mutations?[1] If you have a RAS-targeting drug development strategy, you’ll want to access our 56 unique PDX cancer models and companion PDX-derived 3D cell culture models with the most common RAS activations for preclinical validation. Download the data pack now: https://hubs.la/Q02vZSW60. #KRAS #RAS #TargetedTherapies #DrugDevelopment #CancerResearch #AACR24 [1] New Drugs on the Horizon: Part 1, AACR 2024 Annual Meeting; April 7.

"Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic agents to precisely target and eliminate cancer cells." In our latest blog, Translational Drug Development (TD2) shares several key trends that are shaping the future of ADC development. Read it now: https://lnkd.in/gQ7pr2hQ

Translational Drug Development (TD2) understands the nuances of Antibody Drug Conjugate (#ADC) development from the "Bench-to-Bedside." DM or email (mkoratich@td2inc.com) if you would like to learn more! #ADC #antibodydrugconjugate #cancertherapeutic #preclinical #regulatoryconsulting #ind #clinicaldevelopment #clinicaltrial #cro